Modeling the impact of antiretroviral use in developing countries

PLoS Medicine

Volumn 3, Issue 4, 2006, Pages 472-473

  Bertozzi, Stefano M ^a,b   Bautista Arredondo, Sergio ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b CENTRO DE INVESTIGACIÓN Y DOCENCIA ECONÓMICAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPARATIVE STUDY; CONSENSUS; DEVELOPING COUNTRY; DISEASE TRANSMISSION; EPIDEMIC; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MORTALITY; SHORT SURVEY; VIRUS TRANSMISSION; ECONOMICS; HUMAN; NOTE; THEORETICAL MODEL; TREATMENT OUTCOME;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; TREATMENT OUTCOME;

EID: 33646249119     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030148     Document Type: Short Survey

References (12)

1. Paltiel A (2001) Model-based drug evaluation in chronic disease: Promise, pitfalls, and positioning. Drug Inf J 35: 131-139.
2. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS (1997) Primer on medical decision analysis: Part 4 - Analyzing the model and interpreting the results. Med Decis Making 17: 142-151.
3. Pauker SG, Kassirer JP (1980) The threshold approach to clinical decision making. N Engl J Med 302: 1109-1117.
4. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, et al. (1987) Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. Am J Public Health 77: 1417-1426.
5. Hay J, Jackson J (1999) Proceedings of the advisory panel meeting and conference on pharmacoeconomic issues: Panel 2: Methodolgoical issues in conducting pharmacoeconomic evaluations - Modeling studies. Value Health 2: 78-81.
6. Baggaley RF, Ferguson NM, Garnett GP (2005) The epidemiological impact of antiretroviral use predicted by mathematical models: A review. Emerg Themes Epidemiol 2: 9.
7. Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, et al. (2003) Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 17: 1941-951.
8. Blower SM, Gershengorn HB, Grant RM (2000) A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287: 650-654.
9. Garnett GP, Bartley L, Grassly NC, Anderson RM (2002) Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med 8: 651-654.
10. Over M, Heywood P, Gold J, Gupta I, Hira S, et al. (2004) HIV/AIDS treatment and prevention in India. Modelling the cost and the consequences. Washington (D. C.): World Bank. 156 p.
11. Baggaley RF, Garnett GP, Ferguson NM (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3: e124. DOI: 10.1371/journal.pmed.0030124
12. Bautista-Arredondo S, Mane A, Bertozzi SM (2006) Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: Lessons from Mexico. AIDS 20: 101-109.